GeneDx Quote - WGS

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

77.40

Bid

28.35

Offer

81.00

Volume

668,016

72.25 Day's Range 78.75

2.1149 52 Week Range 89.1099

Market Cap

2.126B

Previous Close

75.30

Open

73.81

Last Trade

78.21

Last Trade Time

Financial Volume

US$ 51,652,538

VWAP

77.3223

Average Volume (3m)

631,527

Shares Outstanding

27,471,397

Dividend Yield

PE Ratio

-12.10

Earnings Per Share (EPS)

-6.4

Revenue

202.57M

Net Profit

-175.77M

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and... GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It also provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. is headquartered in Stamford, Connecticut. Show more

Sector

Blank Checks

Industry

Health Services

Website

www.genedx.com

Headquarters

Wilmington, Delaware, USA

Founded

2020

GeneDx Holdings Corporation is listed in the Blank Checks sector of the NASDAQ with ticker WGS. The last closing price for GeneDx was US$75.30. Over the last year, GeneDx shares have traded in a share price range of US$ 2.1149 to US$ 89.1099.

GeneDx currently has 27,471,397 shares in issue. The market capitalisation of GeneDx is US$2.07 billion. GeneDx has a price to earnings ratio (PE ratio) of -12.10.

Overall Flow

Bullish

Net Premium

157k

Calls / Puts

100.00%

Buys / Sells

50.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

GeneDx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the 43rd Annual J.P. Morgan Healthcare...

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Biogen (Nasdaq: BIIB), Praxis Precision Medicines (Nasdaq: PRAX) and Stoke...

GeneDx to Participate in Upcoming Investor Conference

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in the Piper Sandler 36th Annual...

GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover

New Biopharma Solution Aims to Accelerate the Delivery of Precision Medicine to More Patients GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today...

GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary

Veteran Legal Executive from Zoetis and Pfizer Joins GeneDx Executive Leadership Team to Lead Legal, Compliance and Policy Functions GeneDx (Nasdaq: WGS), a leader in delivering improved health...

New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic Yields

Data demonstrates the strength of GeneDx’s diverse database; exome diagnostic rate is high regardless of patient’s ancestral background GeneDx industry leading dataset from 46% non-white...

GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting

Data to be presented showcasing GeneDx’s ongoing commitment to spearheading industry-leading research to drive transformational clinical utility GeneDx (Nasdaq: WGS), a leader in delivering...

GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights

Achieved profitability milestone with third quarter adjusted net income1 of $1.2M Reported third quarter 2024 revenues2 of $76.6M with 77% year-over-year growth of exome and genome test...

Groundbreaking GUARDIAN Study Shows Benefits of Adding Genome Sequencing to Newborn Screening; Augments and Improves Standard Newborn Screening

Findings published today in JAMA (Journal of the American Medical Association) reveal limitations of current screening methods and showcase the promise of advanced genomic technology to deliver...

GeneDx to Showcase Data from Largest Genomic Newborn Screening Cohort of 14,000 Newborns

Data to be presented at the International Conference on Newborn Sequencing (ICoNS) highlighting lessons learned from the GUARDIAN and Early Check newborn sequencing studies showcasing GeneDx’s...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	3.79	5.14875696237	73.61	83.78	70.69	630273	77.76732888	CS
4	4.85	6.68504479669	72.55	84.77	70.27	529277	77.31304522	CS
12	36.65	89.9386503067	40.75	89.1099	40.1386	631527	69.60760646	CS
26	49.43	176.725062567	27.97	89.1099	24.91	524692	53.1555094	CS
52	75.22	3450.4587156	2.18	89.1099	2.1149	450662	37.0501668	CS
156	66.477	608.596539412	10.923	89.1099	1.16	947844	18.21694726	CS
260	66.477	608.596539412	10.923	89.1099	1.16	947844	18.21694726	CS

WGS - Frequently Asked Questions (FAQ)

What is the current GeneDx share price?

The current share price of GeneDx is US$ 77.40

How many GeneDx shares are in issue?

GeneDx has 27,471,397 shares in issue

What is the market cap of GeneDx?

The market capitalisation of GeneDx is USD 2.07B

What is the 1 year trading range for GeneDx share price?

GeneDx has traded in the range of US$ 2.1149 to US$ 89.1099 during the past year

What is the PE ratio of GeneDx?

The price to earnings ratio of GeneDx is -12.1

What is the cash to sales ratio of GeneDx?

The cash to sales ratio of GeneDx is 10.5

What is the reporting currency for GeneDx?

GeneDx reports financial results in USD

What is the latest annual turnover for GeneDx?

The latest annual turnover of GeneDx is USD 202.57M

What is the latest annual profit for GeneDx?

The latest annual profit of GeneDx is USD -175.77M

What is the registered address of GeneDx?

The registered address for GeneDx is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

What is the GeneDx website address?

The website address for GeneDx is www.genedx.com

Which industry sector does GeneDx operate in?

GeneDx operates in the HEALTH SERVICES sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
MYSZMy Size Inc	US$ 4.2001 (211.12%)	121.03M
NVNINVNI Group Ltd	US$ 8.26 (209.36%)	78.06M
TPICTPI Composites Inc	US$ 2.45 (100.82%)	34M
ICGIntchains Group Ltd	US$ 8.77 (88.60%)	527.94k
HSDTHelius Medical Technologies Inc	US$ 0.884851 (84.34%)	121.95M
CYNCYNGN Inc	US$ 0.4603 (-71.41%)	27.91M
MTEMMolecular Templates Inc	US$ 0.1502 (-57.09%)	8.75M
PRFXPainReform Ltd	US$ 5.15 (-53.85%)	2.94M
GALTGalectin Therapeutics Inc	US$ 1.03 (-48.50%)	9.27M
BCABBioAtla Inc	US$ 0.6923 (-41.82%)	6.25M
EDBLEdible Garden AG Inc	US$ 0.24 (65.06%)	354.33M
NVDANVIDIA Corporation	US$ 134.70 (3.08%)	310.19M
APTOAptose Biosciences Inc	US$ 0.28 (64.51%)	306.25M
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.606999 (6.49%)	293.22M
PLTRPalantir Technologies Inc	US$ 80.55 (8.54%)	281.23M